Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibitor of JA K2 and IRA K1
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:class |
gptkb:Cloud_Computing_Service
|
| gptkbp:clinical_trial |
Phase 3
hematologic malignancies PA C203 PACIFICA |
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:developed_by |
CTI Bio Pharma
|
| gptkbp:dosage_form |
200 mg once daily
|
| gptkbp:formulation |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pacritinib
|
| gptkbp:indication |
myelofibrosis with thrombocytopenia
|
| gptkbp:ingredients |
C22 H24 N4 O3 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_a_route_for |
hepatic
|
| gptkbp:is_used_for |
treatment of myelofibrosis
|
| gptkbp:lifespan |
approximately 4 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
CTI Bio Pharma Corp.
|
| gptkbp:marketed_as |
brand name Pacritinib
|
| gptkbp:side_effect |
gptkb:historical_event
gptkb:fandom anxiety dizziness fatigue headache muscle pain nausea hypertension weight loss abdominal pain fever swelling vomiting chest pain diarrhea rash hearing loss insomnia constipation dry mouth chills shortness of breath nervousness sweating liver enzyme elevation hair loss thrombocytopenia infection risk tremors hypotension palpitations thirst visual disturbances nail changes peripheral edema skin discoloration |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
JA K2
IRA K1 |
| gptkbp:year |
gptkb:2022
|
| gptkbp:year_created |
gptkb:2012
|
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
|
| gptkbp:bfsLayer |
5
|